Brian is Co-Founder and General Partner of the Yield Lab Ireland Accelerator and led efforts on behalf of Yield Lab in St Louis to come to Ireland. Brian is also a Co-Founder and Managing Partner of Yield Lab in St Louis, and is a Managing Partner in the Opportunity Fund. In addition to his roles in Yield Lab in St Louis and Yield Lab Ireland, and his role in The Opportunity Fund in the US, he is also Co-Founder and Managing Partner of Prolog Ventures. Brian is responsible for all investment activities, including sourcing, evaluating, structuring, monitoring and exiting deals, and raising capital for the fund itself. Prolog Ventures invests in the healthy living space, which includes agriculture, food and animal health. Brian is a venture capital industry veteran, with over 23 years of experience in the venture capital industry. Prolog’s current Healthy Living Fund has to date invested $26 million across 21 US companies, of which a number have successfully exited, one at 3.9X and another at 4.8X. The portfolio is currently valued at $47m (1.8X) and a total return of $85m (3.3X) is forecast by 2022. Prior to founding Prolog Ventures Brian was founder and CEO of Megan Health, an animal health vaccine company. Brian ran and developed Megan Health from inception to exit. He managed a laboratory of 30 scientists, raised two rounds of financing, negotiated multiple strategic partnerships and successfully sold the company to Pfizer and Avant Immunotherapeutics. Brian is an Immunologist by training and spent 11 years as a postdoc and tenured professor at Washington University. He ran an NIH funded laboratory focused on immune regulation and was director for courses in immunology, histology and cell biology. Subsequently, Brian became President of A/W company, an arm of Alafi Capital, focused on commercializing Washington University technology. He is a highly experienced entrepreneur, operator and venture capital partner. He has been involved in the funding of over 50 VC-backed life science companies.
